Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging

Investigative Radiology

Volumn 42, Issue 12, 2007, Pages 791-796

  Persigehl, Thorsten ^a   Matuszewski, Lars ^a   Kessler, Torsten ^a   Wall, Alexander ^a   Meier, Norbert ^a   Ebert, Wolfgang ^b   Berdel, Wolfgang E ^a   Heindel, Walter ^a   Mesters, Rolf ^a   Bremer, Christoph ^a,c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antiangiogenic; MRI; RGD; Steady state; USPIO; Vascular volume fraction (VVF)

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID PLUS THROMBOPLASTIN; SHU 555C; SODIUM CHLORIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CALIBRATION; CANCER GRADING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; EARLY DIAGNOSIS; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; INOCULATION; MOUSE; MUSCLE TISSUE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; STEADY STATE; TUMOR NECROSIS; XENOGRAFT;

EID: 36248995292     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3180d5cbd9     Document Type: Article

References (37)

1. Herbst RS, Bajorin DF, Bleiberg H, et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol. 2006;24:190-205.
2. Benouchan M, Colombo BM. Anti-angiogenic strategies for cancer therapy [review]. Int J Oncol. 2005;27:563-571.
3. Harris AL. Antiangiogenesis for cancer therapy. Lancet. 1997;349(suppl 2):SII13-SII15.
4. Mousa SA, Mousa AS. Angiogenesis inhibitors: current & future directions. Curr Pharm Des. 2004;10:1-9.
5. Kessler T, Bieker R, Padro T, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005;11:6317-6324.
6. Nilsson F, Kosmehl H, Zardi L, et al. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001;61:711-716.
7. Bremer C, Mustafa M, Bogdanov A Jr, et al. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology. 2003;226:214-220.
8. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol. 2000;34:148-155.
9. Tang JS, Choy G, Bernardo M, et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model. Invest Radiol. 2006;41:691-696.
10. Preda A, van Vliet M, Krestin GP, et al. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol. 2006;41:325-331.
11. Brasch R, Pham C, Shames D, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging. 1997;7:68-74.
12. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006;41:354-362.
13. Holtke C, Wallbrunn AV, Kopka K, et al. A fluorescent photoprobe for the imaging of endothelin receptors. Bioconjug Chem. 2007;18:685-694.
14. Kiessling F, Farhan N, Lichy MP, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia. 2004;6:213-223.
15. Persigehl T, Bieker R, Matuszewski L, et al. Early, non-invasive monitoring of anti-angiogenic tumor treatment by USPIO enhanced MRI. Radiology. Accepted for publication.
16. Bieker R, Kessler T, Persigehl T, et al. Selective infarction of solid tumors in mice by NGR-peptide directed targeting of tissue factor to tumor vasculature. Best abstract 50. Presented at: Annual Meeting of the Society of Thrombosis and Hemostasis, Basel, Switzerland, 2006.
17. Hu P, Yan J, Sharifi J, et al. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003;63:5046-5053.
18. Schraa AJ, Kok RJ, Moorlag HE, et al. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer. 2002;102:469-475.
19. Reimer P, Bremer C, Allkemper T, et al. Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebo-controlled clinical phase I study. Radiology. 2004;231:474-481.
20. Allkemper T, Bremer C, Matuszewski L, et al. Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology. 2002;223:432-438.
21. Tombach B, Reimer P, Bremer C, et al. First pass- and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study. NMR Biomed. 2004;3:500-506.
22. Tombach B, Reimer P, Mahler M, et al. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad Radiol. 2002;9(suppl 2):S425-S427.
23. Boxerman JL, Hamberg LM, Rosen BR, et al. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med. 1995;34:555-566.
24. Dennie J, Mandeville JB, Boxerman JL, et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med. 1998;40:793-799.
25. Bremer C, Matuszewski L, Meier N, et al. Contrast enhanced MR imaging with clinically approved iron oxides fort the assessment of bone marrow angiogenesis in patients with acute myeloid leukemia. Radiology. 2003;229:432.
26. Renger BC, Schuierer G, Meier N. Perfusion, diffusion and functional imaging parameter images with a single application. In: Lemke HU, Vannier MW, Inamura K, eds. Computer Assisted Radiology and Surgery. The Netherlands: Elsevier Publishers; 1997:133-136.
27. Zhu H, Melder RJ, Baxter LT, et al. Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res. 1996;56:3771-3781.
28. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
29. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67:1555-1562.
30. Persigehl T, Heindel W, Bremer C. MR and optical approaches to molecular imaging. Abdom Imaging. 2005;30:342-354.
31. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15:621-628.
32. Muller-Schimpfle M, Brix G, Layer G, et al. Recurrent rectal cancer: diagnosis with dynamic MR imaging. Radiology. 1993;189:881-889.
33. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology. 2005;237:492-499.
34. Turetschek K, Huber S, Floyd E, et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001;218:562-569.
35. Kim YR, Yudina A, Figueiredo J, et al. Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res. 2005;65:9253-9260.
36. Reichardt W, Hu-Lowe D, Torres D, et al. Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model. Neoplasia. 2005;7:847-853.
37. Matuszewski L, Persigehl T, Wall A, et al. Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: initial experience. Radiology. 2007;242:217-224.